If you are buying a compounded product and plan to mention it to a doctor or pharmacist, this is a survey about what that person is likely to know. It is not a survey about the products, which is a different question with its own contested evidence.
What was asked, and of whom
A fourteen-item survey went to clinicians and pharmacists who regularly care for patients prescribed a GLP-1 or dual agonist across one multi-site health system. [1] 523 were distributed and 99 eligible responses were analyzed.
Under a fifth replied, which matters more than usual here: a survey about a contested product attracts people who have an opinion about it. The 99 are not a random fifth of the 523, and nothing in the design makes them one.
What they said
51% knew about the 2024 American Diabetes Association guidance statement on compounded GLP-1 and dual agonist products. Just under half did not.
A majority reported low confidence in these products’ safety and had not incorporated them into practice, citing safety, efficacy, legality and gaps in their own knowledge. Many asked for more education — which is a fair request, given how little of the clinical evidence on copies exists to teach.
What the authors expect
That compounded use continues despite regulatory changes and is likely to persist, and that knowledge gaps may be limiting appropriate use even while clinicians recognize the cost and access argument for these products.
That is a more careful position than either side of this usually takes. Compounded products exist because the branded ones are unaffordable for most of the people who qualify, which is the finding behind most eligible patients declining on price, and pretending the demand is irrational does not make it go away.
What a buyer does with it
Expect to be the more informed party in the conversation, and do not read a clinician’s hesitation as a verdict on your particular product.
The thing worth establishing is the dispensing route, because which kind of pharmacy prepared it determines what oversight applied, and that is a question with an answer rather than an opinion. One health system in one month is not a national picture, and regulation here moves faster than survey research does.